Literature DB >> 20600907

Engineering DYRK1A overdosage yields Down syndrome-characteristic cortical splicing aberrations.

Debra Toiber1, Garikoitz Azkona, Shani Ben-Ari, Nuria Torán, Hermona Soreq, Mara Dierssen.   

Abstract

Down syndrome (DS) associates with impaired brain functions, but the underlying mechanism(s) are yet unclear. The "gene dosage" hypothesis predicts that in DS, overexpression of a single gene can impair multiple brain functions through a signal amplification effect due to impaired regulatory mechanism(s). Here, we report findings attributing to impairments in the splicing process such a regulatory role. We have used DS fetal brain samples in search for initial evidence and employed engineered mice with MMU16 partial trisomy (Ts65Dn) or direct excess of the splicing-associated nuclear kinase Dyrk1A, overdosed in DS for further analyses. We present specific albeit modest changes in the DS brain's splicing machinery with subsequently amplified effects in target transcripts; and we demonstrate that engineered excess of Dyrk1A can largely recapitulate these changes. Specifically, in both the fetal DS brains and the Dyrk1A overdose models, we found ample modestly modified splicing-associated transcripts which apparently induced secondary enhancement in exon inclusion of key synaptic transcripts. Thus, DS-reduced levels of the dominant-negative TRKBT1 transcript, but not other TRKB mRNA transcripts, were accompanied by corresponding decreases in BDNF. In addition, the DS brains and Dyrk1A overdosage models showed selective changes in the transcripts composition of neuroligin mRNAs as well as reductions in the "synaptic" acetylcholinesterase variant AChE-S mRNA and corresponding increases in the stress-inducible AChE-R mRNA variant, yielding key synaptic proteins with unusual features. In cotransfected cells, Dyrk1A overdosage caused parallel changes in the splicing pattern of an AChE mini-gene, suggesting that Dyrk1A overdosage is both essential and sufficient to induce the observed change in the composition of AChE mRNA variants. Furthermore, the Dyrk1A overdosage animal models showed pronounced changes in the structure of neuronal nuclear speckles, where splicing events take place and in SR proteins phosphorylation known to be required for the splicing process. Together, our findings demonstrate DS-like brain splicing machinery malfunctioning in Dyrk1A overexpressing mice. Since individual splicing choices may alter cell fate determination, axon guidance, and synaptogenesis, these findings suggest the retrieval of balanced splicing as a goal for DS therapeutic manipulations early in DS development. (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20600907     DOI: 10.1016/j.nbd.2010.06.011

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  21 in total

1.  BDNF and DYRK1A are variable and inversely correlated in lymphoblastoid cell lines from Down syndrome patients.

Authors:  Asma Tlili; Alexander Hoischen; Clémentine Ripoll; Eva Benabou; Anne Badel; Anne Ronan; Renaud Touraine; Yann Grattau; Samantha Stora; Bregje van Bon; Bert de Vries; Björn Menten; Nele Bockaert; Joseph Gecz; Stylianos E Antonarakis; Dominique Campion; Marie-Claude Potier; Henri Bléhaut; Jean-Maurice Delabar; Nathalie Janel
Journal:  Mol Neurobiol       Date:  2012-06-05       Impact factor: 5.590

2.  LPS-Induced Inflammation Abolishes the Effect of DYRK1A on IkB Stability in the Brain of Mice.

Authors:  Alizée Latour; Yuchen Gu; Nadim Kassis; Fabrice Daubigney; Catherine Colin; Blandine Gausserès; Sandrine Middendorp; Jean-Louis Paul; Valérie Hindié; Jean-Christophe Rain; Jean-Maurice Delabar; Eugene Yu; Mariona Arbones; Michel Mallat; Nathalie Janel
Journal:  Mol Neurobiol       Date:  2018-05-30       Impact factor: 5.590

Review 3.  Down syndrome: the brain in trisomic mode.

Authors:  Mara Dierssen
Journal:  Nat Rev Neurosci       Date:  2012-12       Impact factor: 34.870

4.  Evidence that increased Kcnj6 gene dose is necessary for deficits in behavior and dentate gyrus synaptic plasticity in the Ts65Dn mouse model of Down syndrome.

Authors:  Alexander M Kleschevnikov; Jessica Yu; Jeesun Kim; Larisa V Lysenko; Zheng Zeng; Y Eugene Yu; William C Mobley
Journal:  Neurobiol Dis       Date:  2017-03-22       Impact factor: 5.996

5.  Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk).

Authors:  Andrew S Rosenthal; Cordelle Tanega; Min Shen; Bryan T Mott; James M Bougie; Dac-Trung Nguyen; Tom Misteli; Douglas S Auld; David J Maloney; Craig J Thomas
Journal:  Bioorg Med Chem Lett       Date:  2011-03-04       Impact factor: 2.823

Review 6.  Neurological phenotypes for Down syndrome across the life span.

Authors:  Ira T Lott
Journal:  Prog Brain Res       Date:  2012       Impact factor: 2.453

7.  MiR-1246: a new link of the p53 family with cancer and Down syndrome.

Authors:  Jun-Ming Liao; Xiang Zhou; Yu Zhang; Hua Lu
Journal:  Cell Cycle       Date:  2012-07-15       Impact factor: 4.534

8.  Molecular rescue of DYRK1A overexpression in cystathionine beta synthase-deficient mouse brain by enriched environment combined with voluntary exercise.

Authors:  Benoit Souchet; Alizée Latour; Yuchen Gu; Fabrice Daubigney; Jean-Louis Paul; Jean-Maurice Delabar; Nathalie Janel
Journal:  J Mol Neurosci       Date:  2014-05-13       Impact factor: 3.444

Review 9.  Mouse models of Down syndrome as a tool to unravel the causes of mental disabilities.

Authors:  Noemí Rueda; Jesús Flórez; Carmen Martínez-Cué
Journal:  Neural Plast       Date:  2012-05-22       Impact factor: 3.599

Review 10.  Molecular and cellular alterations in Down syndrome: toward the identification of targets for therapeutics.

Authors:  Nicole Créau
Journal:  Neural Plast       Date:  2012-07-12       Impact factor: 3.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.